Alatrofloxacin

Jump to: navigation, search
Alatrofloxacin
250px
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Intravenous
Legal status
Legal status
  • Withdrawn
Pharmacokinetic data
BioavailabilityN/A
Protein binding76% (trovafloxacin)
MetabolismQuickly hydrolyzed to trovafloxacin
Elimination half-life9 to 12 hours (trovafloxacin)
ExcretionFecal and renal (trovafloxacin)
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC26H25F3N6O5
Molar mass558.509 g/mol

WikiDoc Resources for Alatrofloxacin

Articles

Most recent articles on Alatrofloxacin

Most cited articles on Alatrofloxacin

Review articles on Alatrofloxacin

Articles on Alatrofloxacin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Alatrofloxacin

Images of Alatrofloxacin

Photos of Alatrofloxacin

Podcasts & MP3s on Alatrofloxacin

Videos on Alatrofloxacin

Evidence Based Medicine

Cochrane Collaboration on Alatrofloxacin

Bandolier on Alatrofloxacin

TRIP on Alatrofloxacin

Clinical Trials

Ongoing Trials on Alatrofloxacin at Clinical Trials.gov

Trial results on Alatrofloxacin

Clinical Trials on Alatrofloxacin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Alatrofloxacin

NICE Guidance on Alatrofloxacin

NHS PRODIGY Guidance

FDA on Alatrofloxacin

CDC on Alatrofloxacin

Books

Books on Alatrofloxacin

News

Alatrofloxacin in the news

Be alerted to news on Alatrofloxacin

News trends on Alatrofloxacin

Commentary

Blogs on Alatrofloxacin

Definitions

Definitions of Alatrofloxacin

Patient Resources / Community

Patient resources on Alatrofloxacin

Discussion groups on Alatrofloxacin

Patient Handouts on Alatrofloxacin

Directions to Hospitals Treating Alatrofloxacin

Risk calculators and risk factors for Alatrofloxacin

Healthcare Provider Resources

Symptoms of Alatrofloxacin

Causes & Risk Factors for Alatrofloxacin

Diagnostic studies for Alatrofloxacin

Treatment of Alatrofloxacin

Continuing Medical Education (CME)

CME Programs on Alatrofloxacin

International

Alatrofloxacin en Espanol

Alatrofloxacin en Francais

Business

Alatrofloxacin in the Marketplace

Patents on Alatrofloxacin

Experimental / Informatics

List of terms related to Alatrofloxacin


Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions.[2][3]

Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.

References

  1. "PubChem CID 5489474".
  2. Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. PMID 14568230.
  3. Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ. 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMID 16735322.




Linked-in.jpg